Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
March 16, 2023 08:30 ET
|
Journey Medical Corporation
Subjects completed 16-week treatment with no significant safety issues Topline results expected in the first half of 2023 SCOTTSDALE, Ariz., March 16, 2023 (GLOBE NEWSWIRE) --...
Journey Medical Corporation to Participate in the 35th Annual ROTH Conference
March 07, 2023 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that focuses on the development and...
Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer
January 20, 2023 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the...
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea
January 10, 2023 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29
December 20, 2022 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company focused on the development and...
Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
December 05, 2022 16:05 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 10, 2022 16:01 ET
|
Journey Medical Corporation
Revenue for the first nine months of 2022 increased 26% to $57.7 million versus the same period in 2021 of $45.6 million DFD-29 Phase 3 studies are 75% enrolled to date Top-line data from the Phase...
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022
November 03, 2022 08:52 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences
October 04, 2022 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and...
Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea
August 30, 2022 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and...